| Description |
Reversin 121 is a P-glycoprotein inhibitor. Reversin 121 increases the ATPase activity of MDR1. Reversin 121 reverses P-glycoprotein-mediated multidrug resistance. Reversin 121 can be used in the research of cancers[1][2].
|
| Related Catalog |
|
| Target |
P-glycoprotein[1]
|
| In Vitro |
Reversin 121 (12 μg/mL) (with gemcitabine (HY-17026)) reduces the proportions of tumor cells positive for MDR proteins in Panc1 cell[1]. Reversin 121 (5 μM) reverses the resistance against paclitaxel in paclitaxel-resistant NCI-H460 cell[2]. Reversin 121 (10 μM, 48 h) inhibits T cell proliferation[3].
|
| In Vivo |
Reversin 121 (2.5 mg/kg, plus 5-fluorouracil, 35 mg/kg/day, i.p.) decreases tumor size and prevalence of metastases[1]. Animal Model: Orthotopic pancreatic carcinoma mouse model[1]. Dosage: 2.5 mg/kg, plus 5-fluorouracil, 35 mg/kg/day Administration: Intraperitoneal injection (i.p.), 5 days a week Result: Decreased in MRP3-positive cells.
|
